secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001628280-25-005406
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q4 2024 revenue $53.2M (+17% YoY); guides 2025 rev $210-250M
------------------------------------------------------------------

- Q4 2024 net loss $4.9M vs $2.4M loss in Q4 2023; Fanapt sales $26.6M (+18% YoY).
- Full year 2024 revenue $198.8M (+3%); net loss $18.9M vs net income $2.5M in 2023.
- 2025 revenue guidance $210-250M; targets psychiatry portfolio >$750M by 2030.
- Bysanti NDA for bipolar/schizophrenia expected Q1 2025; Tradipitant NDA for motion sickness submitted Q4 2024.
- Imsidolimab BLA for generalized pustular psoriasis expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/0001628280-25-005406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/vnda-20250213.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-005406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer